Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine.
Barbara Ann Karmanos Cancer Institute, Detroit.
Otol Neurotol. 2018 Oct;39(9):1172-1183. doi: 10.1097/MAO.0000000000001925.
To perform a systematic review evaluating etiologies, associated complications, and management of osteoradionecrosis of the temporal bone (ORNTB).
The authors searched the PubMed, Embase, and Cochrane Library databases for relevant literature. Patient demographics, etiologies, treatments, and other clinical characteristics were obtained. Treatment success was defined as resolution of symptoms at last follow-up. Results were reported using the preferred reporting systems for systematic reviews and meta-analysis (PRISMA) guidelines.
Thirty-eight studies encompassing 364 patients with ORNTB were identified. The most common etiologies necessitating radiotherapy included: nasopharyngeal carcinoma (n = 133 [36.8%]), parotid tumors (n = 73 [20.2%]), and external auditory canal pathology (n = 59 [16.3%]). The mean dose of radiation was 58.0 Gy. The mean lag time between radiotherapy and osteoradionecrosis (ORN) symptoms was 7.9 years. The most common presenting symptoms were purulent otorrhea (33.3%), hearing loss (29.1%), and otalgia (17%). ORNTB complications included tympanic membrane perforation (n = 102 [63.8%]) and chronic otitis media (n = 16 [10%]). Treatments included lateral temporal bone resection (n = 99 [28.3%]), conservative treatment (n = 92 [26.3%]), and mastoidectomy (n = 82 [23.5%]) with 90.9, 89.13, and 59.76% considered successful, respectively.
ORNTB is a rare complication of radiotherapy that may present years after initial radiation exposure. Management should be aimed at relief of presenting symptoms and treatment of ORNTB associated complications. Both conservative and surgical measures may adequately control the disease process and symptomatology; however, randomized controlled studies comparing treatments would serve to further corroborate these findings.
对颞骨放射性骨坏死(ORNBT)的病因、相关并发症及治疗进行系统评价。
作者检索了 PubMed、Embase 和 Cochrane Library 数据库中相关文献。获取患者人口统计学资料、病因、治疗方法及其他临床特征。治疗成功定义为末次随访时症状缓解。研究结果采用系统评价和荟萃分析的首选报告系统(PRISMA)指南进行报告。
共纳入 38 项研究,涉及 364 例 ORNBT 患者。最常见的需要放疗的病因包括:鼻咽癌(n=133 [36.8%])、腮腺肿瘤(n=73 [20.2%])和外耳道病变(n=59 [16.3%])。放射剂量的平均值为 58.0 Gy。放疗后至 ORN 症状出现的平均潜伏期为 7.9 年。最常见的首发症状是脓性耳漏(33.3%)、听力损失(29.1%)和耳痛(17%)。ORNBT 的并发症包括鼓膜穿孔(n=102 [63.8%])和慢性中耳炎(n=16 [10%])。治疗方法包括颞骨外侧切除术(n=99 [28.3%])、保守治疗(n=92 [26.3%])和乳突切除术(n=82 [23.5%]),成功率分别为 90.9%、89.13%和 59.76%。
ORNBT 是放疗的罕见并发症,可能在初始放疗后数年出现。治疗应针对缓解现有症状和治疗 ORNBT 相关并发症。保守治疗和手术治疗均可有效控制疾病过程和症状,但比较治疗方法的随机对照研究将有助于进一步证实这些发现。